453 related articles for article (PubMed ID: 29309058)
1. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.
Bezzi M; Seitzer N; Ishikawa T; Reschke M; Chen M; Wang G; Mitchell C; Ng C; Katon J; Lunardi A; Signoretti S; Clohessy JG; Zhang J; Pandolfi PP
Nat Med; 2018 Feb; 24(2):165-175. PubMed ID: 29309058
[TBL] [Abstract][Full Text] [Related]
2. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
3. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
4. Increased T-cell Infiltration Elicited by
Loveridge CJ; Mui EJ; Patel R; Tan EH; Ahmad I; Welsh M; Galbraith J; Hedley A; Nixon C; Blyth K; Sansom O; Leung HY
Cancer Res; 2017 Jun; 77(12):3158-3168. PubMed ID: 28515147
[TBL] [Abstract][Full Text] [Related]
5. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
Wang G; Lunardi A; Zhang J; Chen Z; Ala U; Webster KA; Tay Y; Gonzalez-Billalabeitia E; Egia A; Shaffer DR; Carver B; Liu XS; Taulli R; Kuo WP; Nardella C; Signoretti S; Cordon-Cardo C; Gerald WL; Pandolfi PP
Nat Genet; 2013 Jul; 45(7):739-746. PubMed ID: 23727861
[TBL] [Abstract][Full Text] [Related]
6. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
7. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
8. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
9. The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance.
Di Carlo E; D'Antuono T; Pompa P; Giuliani R; Rosini S; Stuppia L; Musiani P; Sorrentino C
Clin Cancer Res; 2009 May; 15(9):2979-87. PubMed ID: 19366834
[TBL] [Abstract][Full Text] [Related]
10. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer.
Zhang H; Melamed J; Wei P; Cox K; Frankel W; Bahnson RR; Robinson N; Pyka R; Liu Y; Zheng P
Cancer Immun; 2003 Feb; 3():2. PubMed ID: 12747744
[TBL] [Abstract][Full Text] [Related]
11. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-200c Promotes Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating PTEN and FOG2 Expression.
Mei S; Xin J; Liu Y; Zhang Y; Liang X; Su X; Yan H; Huang Y; Yang R
PLoS One; 2015; 10(8):e0135867. PubMed ID: 26285119
[TBL] [Abstract][Full Text] [Related]
13. SLUG is a direct transcriptional repressor of PTEN tumor suppressor.
Uygur B; Abramo K; Leikina E; Vary C; Liaw L; Wu WS
Prostate; 2015 Jun; 75(9):907-16. PubMed ID: 25728608
[TBL] [Abstract][Full Text] [Related]
14. Timp3 loss accelerates tumour invasion and increases prostate inflammation in a mouse model of prostate cancer.
Adissu HA; McKerlie C; Di Grappa M; Waterhouse P; Xu Q; Fang H; Khokha R; Wood GA
Prostate; 2015 Dec; 75(16):1831-43. PubMed ID: 26332574
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
[TBL] [Abstract][Full Text] [Related]
16. IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer.
Pencik J; Wiebringhaus R; Susani M; Culig Z; Kenner L
Swiss Med Wkly; 2015; 145():w14215. PubMed ID: 26691865
[TBL] [Abstract][Full Text] [Related]
17. Generation of PTEN‑knockout (‑/‑) murine prostate cancer cells using the CRISPR/Cas9 system and comprehensive gene expression profiling.
Takao A; Yoshikawa K; Karnan S; Ota A; Uemura H; De Velasco MA; Kura Y; Suzuki S; Ueda R; Nishino T; Hosokawa Y
Oncol Rep; 2018 Nov; 40(5):2455-2466. PubMed ID: 30226608
[TBL] [Abstract][Full Text] [Related]
18. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
19. A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.
Tamborero D; Rubio-Perez C; Muiños F; Sabarinathan R; Piulats JM; Muntasell A; Dienstmann R; Lopez-Bigas N; Gonzalez-Perez A
Clin Cancer Res; 2018 Aug; 24(15):3717-3728. PubMed ID: 29666300
[No Abstract] [Full Text] [Related]
20. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors.
Min JN; Huang L; Zimonjic DB; Moskophidis D; Mivechi NF
Oncogene; 2007 Aug; 26(35):5086-97. PubMed ID: 17310987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
